成釉细胞瘤的非手术治疗进展

doi:10.3760/cma.j.cn113030-20200429-00225

摘要
图/表
参考文献(58)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要成釉细胞瘤是较为常见的牙源性良性肿瘤,具有局部浸润生长﹑易复发、转移等特性。目前,主要治疗方式是扩大性骨切除术,但术后复发率高,且易出现面部、功能畸形等诸多并发症。对于无法手术患者,放疗、化学药物、靶向治疗等治疗可在保留器官下改善预后,本文复习成釉细胞瘤的非手术治疗现状和进展,为成釉细胞瘤个体化治疗提供依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	金一
	杨锫
	金和坤
	吴湘玮
	王晖

关键词 ：成釉细胞瘤/放射疗法, 成釉细胞瘤/化学疗法, 成釉细胞瘤/分子靶向疗法, 研究进展

Abstract：Ameloblastoma is a relatively common benign tumor that occurs in the dental epithelial tissues, which is characterized with local infiltration and growth,high-risk recurrence and metastasis, etc. At present, radical osteotomy is the main treatment of ameloblastoma, whereas it yields high recurrence rate and causes multiple postoperative complications such as facial and functional deformities, etc. For inoperable patients, non-surgical interventions, such as radiotherapy, chemotherapy and molecule-targeted therapy, are urgently needed to improve prognosis and retain organs. This article summarizes the current status and research progresses on non-surgical treatment of ameloblastoma, aiming to provide evidence for individualized treatment of ameloblastoma.

Key words： Ameloblastoma/radiotherapy Ameloblastoma/chemotherapy Ameloblastoma/molecule-targeted therapy Research progress

收稿日期: 2020-04-29

基金资助:肿瘤放疗转化医学湖南省重点实验室项目(2015TP1009);湖南省重点研发计划项目(2018SK2123);湖南省肿瘤医院启航青年培育基金(QH201905)

通讯作者: 王晖,Email:wanghui710327@163.com

引用本文:

金一,杨锫,金和坤等. 成釉细胞瘤的非手术治疗进展[J]. 中华放射肿瘤学杂志, 2022, 31(1): 85-89.

Jin Yi,Yang Pei,Jin Hekun et al. Research progress on non-surgical treatment of ameloblastoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(1): 85-89.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200429-00225 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I1/85

[1] ALMEIDA-RDE A, ANDRADE ES, BARBALHO JC, et al. Recurrence rate following treatment for primary multicystic ameloblastoma:systematic review and meta-analysis[J]. Int J Oral Maxillofac Surg, 2016, 45(3):359-367. DOI:10.1016/j.ijom.2015.12.016.
[2] AGBAJE JO, OLUMUYIWA-ADISA A, IVANOVA-PETROVA M, et al. Biological profile of ameloblastoma and its location in the jaw in 1246 Nigerians[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(5):424-431. DOI:10.1016/j.oooo.2018.06.014.
[3] BROWN NA, BETZ BL. Ameloblastoma:a review of recent molecular pathogenetic discoveries[J]. Biomark Cancer, 2015, 7(Suppl 2):19-24. DOI:10.4137/BIC. S29329.
[4] JUSSILA M, THESLEFF I. Signaling networks regulating tooth organogenesis and regeneration, and the specification of dental mesenchymal and epithelial cell lineages[J]. Cold Spring Harb Perspect Biol, 2012, 4(4):a008425. DOI:10.1101/cshperspect.a008425.
[5] ALVES DBM, TUJI FM, ALVES FA, et al. Evaluation of mandibular odontogenic keratocyst and ameloblastoma by panoramic radiograph and computed tomography[J]. Dentomaxillofac Radiol, 2018, 47(7):20170288. DOI:10.1259/dmfr.20170288.
[6] ABE M, ZONG L, ABE T, et al. A turning point in therapy for ameloblastomas[J]. Oral Oncol, 2018, 80:95-96. DOI:10.1016/j.oraloncology.2018.03.007.
[7] AU SW, LI KY, CHOI WS, et al. Risk factors for recurrence of ameloblastoma:a long-term follow-up retrospective study[J]. Int J Oral Maxillofac Surg, 2019, 48(10):1300-1306. DOI:10.1016/j.ijom.2019.04.008.
[8] ECKARDT AM, KOKEMüLLER H, FLEMMING P, et al. Recurrent ameloblastoma following osseous reconstruction—a review of twenty years[J]. J Craniomaxillofac Surg, 2009, 37(1):36-41. DOI:10.1016/j.jcms.2008.07.009.
[9] SEHDEV MK, HUVOS AG, STRONG EW, et al. Proceedings:ameloblastoma of maxilla and mandible[J]. Cancer, 1974, 33(2):324-333. DOI:10.1002/1097-0142(197402)33:2<324::aid-cncr2820330205>3.0.co;2-u.
[10] VANOVEN BJ, PARKER NP, PETRUZZELLI GJ. Peripheral ameloblastoma of the maxilla:a case report and literature review[J]. Am J Otolaryngol, 2008, 29(5):357-360. DOI:10.1016/j.amjoto.2007.10.002.
[11] MCCLARY AC, WEST RB, MCCLARY AC, et al. Ameloblastoma:a clinical review and trends in management[J]. Eur Arch Otorhinolaryngol, 2016, 273(7):1649-1661. DOI:10.1007/s00405-015-3631-8.
[12] MILMAN T, YING GS, PAN W, et al. Ameloblastoma:25 year experience at a single institution[J]. Head Neck Pathol, 2016, 10(4):513-520. DOI:10.1007/s12105-016-0734-5.
[13] MURRAY V, HARDIE ME, GAUTAM SD. Comparison of different methods to determine the DNA sequence preference of ionising radiation-induced DNA damage[J]. Genes (Basel), 2019, 11(1). DOI:10.3390/genes11010008.
[14] LEE D, KIM S, PALTA J, et al. A retrospective 4D-MRI based on 2D diaphragm profiles for lung cancer patients[J]. J Med Imaging Radiat Oncol, 2019, 63(3):360-369. DOI:10.1111/1754-9485.12877.
[15] PINSOLLE J, MICHELET V, COUSTAL B, et al. Treatment of ameloblastoma of the jaws[J]. Arch Otolaryngol Head Neck Surg, 1995, 121(9):994-996. DOI:10.1001/archotol.1995.01890090036007.
[16] KENNEDY WR, WERNING JW, KAYE FJ, et al. Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy[J]. Eur Arch Otorhinolaryngol, 2016, 273(10):3293-3297. DOI:10.1007/s00405-016-3899-3.
[17] PETROVIC ID, MIGLIACCI J, GANLY I, et al. Ameloblastomas of the mandible and maxilla[J]. Ear Nose Throat J, 2018, 97(7):E26-E32. DOI:10.1177/014556131809700704.
[18] GUILEMANY JM, BALLESTEROS F,ALõS L, et al. Plexiform ameloblastoma presenting as a sinonasal tumor[J]. Eur Arch Otorhinolaryngol, 2004, 261(6):304-306. DOI:10.1007/s00405-003-0692-x.
[19] EREÑO C, ETXEGARAI L, CORRAL M, et al. Primary sinonasal ameloblastoma[J]. APMIS, 2005, 113(2):148-150. DOI:10.1111/j.1600-0463.2005.apm1130210.x.
[20] ATKINSON CH, HARWOOD AR, CUMMINGS BJ. Ameloblastoma of the jaw. A reappraisal of the role of megavoltage irradiation[J]. Cancer, 1984, 53(4):869-873. DOI:10.1002/1097-0142(19840215)53:4<869::aid-cncr2820530409>3.0.co;2-v.
[21] VALKADINOV I, CONEV N, DZHENKOV D, et al. Rare case of ameloblastoma with pulmonary metastases[J]. Intractable Rare Dis Res, 2017, 6(3):211-214. DOI:10.5582/irdr.2017.01032.
[22] GARDNER DG. Radiotherapy in the treatment of ameloblastoma[J]. Int J Oral Maxillofac Surg, 1988, 17(3):201-205. DOI:10.1016/s0901-5027(88)80033-x.
[23] MIYAMOTO CT, BRADY LW, MARKOE A, et al. Ameloblastoma of the jaw. Treatment with radiation therapy and a case report[J]. Am J Clin Oncol, 1991, 14(3):225-230.
[24] CHEHAL A, LOBO R, NAIM A, et al.Ameloblastoma of the maxillary sinus treated with radiation therapy[J]. Pan Afr Med J, 2017, 26:169. DOI:10.11604/pamj.2017.26.169.8992.
[25] LIU JY, MAN QW, MA YQ, et al. I (125) brachytherapy guided by individual three-dimensional printed plates for recurrent ameloblastoma of the skull base[J]. Br J Oral Maxillofac Surg, 2017, 55(7):e38-e40. DOI:10.1016/j.bjoms.2017.05.019.
[26] AMZERIN M, FADOUKHAIR Z, BELBARAKA R, et al. Metastatic ameloblastoma responding to combination chemotherapy:case report and review of the literature[J]. J Med Case Rep, 2011, 5:491. DOI:10.1186/1752-1947-5-491.
[27] DISSANAYAKE RK, JAYASOORIYA PR, SIRIWARDENA DJ, et al. Review of metastasizing (malignant) ameloblastoma (METAM):pattern of metastasis and treatment[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 111(6):734-741. DOI:10.1016/j.tripleo.2010.12.018.
[28] VERNEUIL A, SAPP P, HUANG C, et al. Malignant ameloblastoma:classification, diagnostic, and therapeutic challenges[J]. Am J Otolaryngol, 2002, 23(1):44-48. DOI:10.1053/ajot.2002.28769.
[29] RICARD AS, MAJOUFRE-LEFEBVRE C, SIBERCHICOT F, et al. A multirecurrent ameloblastoma metastatic to the lung[J]. Rev Stomatol Chir Maxillofac, 2010, 111(2):98-100. DOI:10.1016/j.stomax.2009.06.013.
[30] YANG RN, WANG XS, REN J, et al. Mandible ameloblastoma with lung metastasis:a rare case report[J]. Int J Clin Exp Pathol, 2015, 8(6):6793-6799.
[31] LI D, XU S, SUN M, et al. MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma:a case report[J]. Medicine (Baltimore), 2019, 98(25):e15873. DOI:10.1097/MD.0000000000015873.
[32] GIRIDHAR P, MALLICK S, UPADHYAY AD, et al. Pattern of care and impact of prognostic factors in the outcome of ameloblastic carcinoma:a systematic review and individual patient data analysis of 199 cases[J]. Eur Arch Otorhinolaryngol, 2017, 274(10):3803-3810. DOI:10.1007/s00405-017-4631-7.
[33] HUANG CM, CHEN JY, CHEN CH, et al. Radiotherapy for a repeatedly recurrent ameloblastoma with malignant transformation[J]. Head Neck, 2014, 36(1):E1-3. DOI:10.1002/hed.23257.
[34] CHUANG FH, WANG WC, SHEN YH, et al. Occurrence of ameloblastoma in a patient with nasopharyngeal carcinoma after treatment by irradiation[J]. Spec Care Dentist, 2010, 30(1):27-28. DOI:10.1111/j.1754-4505.2009.00116.x.
[35] BHUYAN SK, BHUYAN R, SAHOO TK, et al. Recurrence of Plexiform Ameloblastoma as Acanthomatous Ameloblastoma:a rare case report[J]. Contemp Clin Dent, 2019, 10(1):178-181. DOI:10.4103/ccd.ccd_505_18.
[36] TANAKA T, OHKUBO T, FUJITSUKA H, et al. Malignant mixed tumor (malignant ameloblastoma and fibrosarcoma) of the maxilla[J]. Arch Pathol Lab Med, 1991, 115(1):84-87.
[37] LI KK, FABIAN RL, GOODMAN ml. Malignant fibrous histiocytoma after radiation for ameloblastoma of the maxilla[J]. J Oral Maxillofac Surg, 1997, 55(1):85-88. DOI:10.1016/s0278-2391(97)90454-7.
[38] GALL JA, SARTIANO GP, SHREINER DP. Ameloblastoma of the mandible with pulmonary metastasis[J]. Oncology, 1975, 32(3-4):118-126. DOI:10.1159/000225058.
[39] RAMADAS K, JOSE CC, SUBHASHINI J, et al. Pulmonary metastases from ameloblastoma of the mandible treated with cisplatin, adriamycin, and cyclophosphamide[J]. Cancer, 1990, 66(7):1475-1479. DOI:10.1002/1097-0142(19901001)66:7<1475::aid-cncr2820660707>3.0.co;2-d.
[40] SHEPPARD BC, TEMECK BK, TAUBENBERGER JK, et al. Pulmonary metastatic disease in ameloblastoma[J]. Chest, 1993, 104(6):1933-1935. DOI:10.1378/chest.104.6.1933.
[41] UEDA M, KANEDA T. Combined chemotherapy and radiotherapy for advanced maxillary ameloblastoma. a case report[J]. J Craniomaxillofac Surg, 1991, 19(6):272-274. DOI:10.1016/s1010-5182(05)80069-1.
[42] CAMPBELL D, JEFFREY RR, WALLIS F, et al. Metastatic pulmonary ameloblastoma. An unusual case[J]. Br J Oral Maxillofac Surg, 2003, 41(3):194-196. DOI:10.1016/s0266-4356(03)00046-9.
[43] GRüNWALD V, LE BLANC S, KARSTENS JH, et al. Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin[J]. Ann Oncol, 2001, 12(10):1489-1491. DOI:10.1023/a:1012522929861.
[44] KURPPA KJ, CATóN J, MORGAN PR, et al. High frequency of BRAF V600E mutations in ameloblastoma[J]. J Pathol, 2014, 232(5):492-498. DOI:10.1002/path.4317.
[45] SWEENEY RT, MCCLARY AC, MYERS BR, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas[J]. Nat Genet, 2014, 46(7):722-725. DOI:10.1038/ng.2986.
[46] BROWN NA, ROLLAND D, MCHUGH JB, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma[J]. Clin Cancer Res, 2014, 20(21):5517-5526. DOI:10.1158/1078-0432. CCR-14-1069
[47] DO CANTO AM, DA SILVA-MARCELINO BMR, SCHUSSEL JL, et al. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas[J]. Clin Oral Investig, 2019, 23(2):779-784. DOI:10.1007/s00784-018-2494-y.
[48] HEIKINHEIMO K, HUHTALA JM, THIEL A, et al. The mutational profile of unicystic ameloblastoma[J]. J Dent Res, 2019, 98(1):54-60. DOI:10.1177/0022034518798810.
[49] GRECO A, SAFI D, SWAMI U, et al. Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors:a systematic review[J]. Cancers (Basel), 2019, 11(12):1950. DOI:10.3390/cancers11121950.
[50] FREGNANI ER, PEREZ DE, PAES DE ALMEIDA O, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness[J]. Histopathology, 2017, 70(3):473-484. DOI:10.1111/his.13095.
[51] KAYE FJ, IVEY AM, DRANE WE, et al. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma[J]. J Natl Cancer Inst, 2015, 107(1):378. DOI:10.1093/jnci/dju378.
[52] FERNANDES GS, GIRARDI DM, BERNARDES JPG, et al. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation[J]. BMC Cancer, 2018, 18(1):887. DOI:10.1186/s12885-018-4802-y.
[53] TAN S, POLLACK JR, KAPLAN MJ, et al. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(1):e5-7. DOI:10.1016/j.oooo.2015.12.016.
[54] ZHANG L, CHEN XM, SUN ZJ, et al. Epithelial expression of SHH signaling pathway in odontogenic tumors[J]. Oral Oncol, 2006, 42(4):398-408. DOI:10.1016/j.oraloncology.2005.09.008.
[55] MISHRA P, PANDA A, BANDYOPADHYAY A, et al. Sonic hedgehog signalling pathway and ameloblastoma-a review[J]. J Clin Diagn Res, 2015, 9(11):ZE10-13. DOI:10.7860/JCDR/2015/15443.6750.
[56] GüLTEKIN SE, AZIZ R, HEYDT C, et al. The landscape of genetic alterations in ameloblastomas relates to clinical features[J]. Virchows Arch, 2018, 472(5):807-814. DOI:10.1007/s00428-018-2305-5.
[57] DEVILLIERS P, SUGGS C, SIMMONS D, et al. Microgenomics of ameloblastoma[J]. J Dent Res, 2011, 90(4):463-469. DOI:10.1177/0022034510391791.
[58] STANTON BZ, PENG LF. Small-molecule modulators of the Sonic Hedgehog signaling pathway[J]. Mol Biosyst, 2010, 6(1):44-54. DOI:10.1039/b910196a.